Disease-modifying anti-rheumatic drugs til behandling af ankyloserende spondylitis

Research output: Contribution to journalJournal articlepeer-review

Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton, peripheral joints, entheses and extra-articular sites. Patients with early disease, a higher level of erythrocyte sedimentation rate and/or peripheral arthritis might benefit from sulfasalazine. Otherwise, there is no evidence that disease-modifying anti-rheumatic (DMARDs) have a therapeutic effect in AS. Clinical evidence that greater TNF-inhibitor effectiveness can be achieved by combining with a DMARD is lacking, but further studies should be performed. More research is needed to clarify the role of DMARDs in the treatment of AS.
Translated title of the contributionDisease-modifying anti-rheumatic drugs for treatment of ankylosing spondylitis
Original languageDanish
JournalUgeskrift for læger
Volume171
Issue number33
Pages (from-to)2268-72
Number of pages5
ISSN0041-5782
Publication statusPublished - 2009

Bibliographical note

Keywords: Antibodies, Monoclonal; Antirheumatic Agents; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Methotrexate; Spondylitis, Ankylosing; Sulfasalazine; Treatment Outcome

ID: 20318991